Objectives: Prostate cancer mortality (PCM) in the USA is among the lowest in the world, whereas PCM in England is among the highest in Europe. This paper aims to assess the association of variation in use of definitive therapy on risk-adjusted PCM in England as compared with the USA.
Design: Observational study.
Setting: Cancer registry data from England and the USA.
Participants: Men diagnosed with non-metastatic prostate cancer (PCa) in England and the USA between 2004 and 2008.
Outcome Measures: Competing-risks survival analyses to estimate subhazard ratios (SHR) of PCM adjusted for age, ethnicity, year of diagnosis, Gleason score (GS) and clinical tumour (cT) stage.
Results: 222,163 men were eligible for inclusion. Compared with American patients, English patients were more likely to present at an older age (70-79 years: England 44.2%, USA 29.3%, p<0.001), with higher tumour stage (cT3-T4: England 25.1%, USA 8.6%, p<0.001) and higher GS (GS 8-10: England 20.7%, USA 11.2%, p<0.001). They were also less likely to receive definitive therapy (England 38%, USA 77%, p<0.001). English patients were more likely to die of PCa (SHR=1.9, 95% CI 1.7 to 2.0, p<0.001). However, this difference was no longer statistically significant when also adjusted for use of definitive therapy (SHR=1.0, 95% CI 1.0 to 1.1, p=0.3).
Conclusions: Risk-adjusted PCM is significantly higher in England compared with the USA. This difference may be explained by less frequent use of definitive therapy in England.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342590 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2014-006805 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: Clinical variables alone have limited ability to determine which patients will have recurrence after radical prostatectomy (RP). We evaluated the ability of locked multimodal artificial intelligence (MMAI) algorithms trained on prostate biopsy specimens to predict prostate cancer specific mortality (PCSM) and overall survival (OS) among patients undergoing radical prostatectomy with digitized RP specimens.
Materials And Methods: The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Randomized Controlled Trial randomized subjects from 1993-2001 to cancer screening or control.
[Role of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) in staging].
Urologie
January 2025
Klinik und Poliklinik für Urologie, Universitätsklinikum Essen, Hufelandstraße 55, 45147, Essen, Deutschland.
The superiority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) over conventional staging methods such as computed tomography (CT) and bone scintigraphy has now been demonstrated for almost all clinical stages of prostate cancer. In primary diagnostics, PSMA-PET/CT is therefore the new standard for risk-adapted whole-body staging. At the same time, PSMA-PET/CT provides a new risk-based classification for predicting overall survival across all early and late stages of the disease.
View Article and Find Full Text PDFImpact of Scanner Manufacturer, Endorectal Coil Use, and Clinical Variables on Deep Learning-assisted Prostate Cancer Classification Using Multiparametric MRI.
Radiol Artif Intell
January 2025
https://www.procancer-i.eu/.
Purpose To assess the impact of scanner manufacturer and scan protocol on the performance of deep learning models to classify prostate cancer (PCa) aggressiveness on biparametric MRI (bpMRI). Materials and Methods In this retrospective study, 5,478 cases from ProstateNet, a PCa bpMRI dataset with examinations from 13 centers, were used to develop five deep learning (DL) models to predict PCa aggressiveness with minimal lesion information and test how using data from different subgroups-scanner manufacturers and endorectal coil (ERC) use (Siemens, Philips, GE with and without ERC and the full dataset)-impacts model performance. Performance was assessed using the area under the receiver operating characteristic curve (AUC).
View Article and Find Full Text PDFStructure and hormonal output of the adrenal gland after experimental estrogenization of male rats.
Histol Histopathol
January 2025
Department of Cytology, Institute for Biological Research "Siniša Stanković" - National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia.
Orchidectomy and estrogenization of the male represent a procedure that is applicable in sex reassignment or in prostate cancer therapy. This approach has an influence on the hypothalamic-pituitary-adrenal axis and thus affects cardiovascular function and metabolism. We utilized orchidectomized rats to evaluate the effects of estradiol on the structure and hormonal output of the adrenal gland.
View Article and Find Full Text PDFAssociation of prostate-specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result.
BJU Int
January 2025
Faculty of Social Sciences (Health Sciences), Prostate Cancer Research Center, Tampere University, Tampere, Finland.
Objective: To assess the association between prostate-specific antigen (PSA) density (PSAD) and prostate cancer mortality after a benign result on systematic transrectal ultrasonography (TRUS)-guided prostate biopsy.
Patients And Methods: This retrospective study used data from the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC) collected between 1996 and 2020. We identified men aged 55-71 years randomised to the screening arm with PSA ≥4.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!